Day One Biopharmaceuticals, Inc.DAWNNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +313.92% | -57.56% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +302.71% | -61.69% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | -150.91% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -181.83% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -153.26% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | -150.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | -150.00% |
| Weighted Average Shares Growth | +12.41% | +7.33% | +18.49% | +18.31% | +6.99% |
| Weighted Average Shares Diluted Growth | +12.78% | +7.33% | +18.49% | +18.31% | +6.65% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | -111.44% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +115.29% | +92.03% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +4233.11% | +158.17% |
| Asset Growth | +45.06% | +54.98% | +63.59% | +29.62% | -14.49% |
| Book Value per Share Growth | +26.82% | +35.17% | +36.34% | +26.99% | -24.14% |
| Debt Growth | +408.75% | +537.75% | +872.00% | +1480.53% | +10.63% |
| R&D Expense Growth | +1.21% | +65.53% | -1.47% | -60.75% | -6.39% |
| SG&A Expenses Growth | +59.40% | +34.75% | +10.91% | -4.03% | -2.85% |